Skip to main content
Signal8

Karyopharm Therapeutics Inc. (KPTI) Form 8-K — Nov 2, 2026

$KPTIForm 8-KItems 1.01, 1.03, 2.03, 2.04, 7.01, 8.01, 9.01Filed Nov 2, 2026, 9:58 PM ET0001193125-26-444164Original filing

Karyopharm Therapeutics (KPTI) filed voluntary Chapter 11 petitions on November 2, 2026 in the U.S. Bankruptcy Court for the Southern District of Texas under a prepackaged plan supported by 100% of its funded debt holders. The plan provides for Ayrmid Ltd. (majority-owned by Highbridge funds) to serve as stalking horse bidder for a merger, with creditors receiving 55% of the reorganized company and Ayrmid's owners 45%, plus contingent value rights tied to future myelofibrosis sales of XPOVIO.

Key figures

Debt Amount
$110 million DIP facility (up to $55 million new money)
Breakup fee
3% of Bid Protection Base
Dip maturity
May 1, 2027
Exit term loan
up to $135 million
Dip rate roll up
SOFR (3.00% floor) + 12.25%
Dip rate new money
SOFR (3.00% floor) + 9.00%
Newco ownership ayrmid
45%
Notes 2028 outstanding
$15.6 million ($15,648,085)
Notes 2029 outstanding
$108.0 million ($107,974,339)
Term loans outstanding
$129.0 million (approx; $128,981,939)
Minimum overbid payment
$363.6 million
Newco ownership creditors
55%
Expected transaction close
Q1 2027
Royalty claims outstanding
$113.5 million ($113,536,880)
Minimum alternative transaction
$335.4 million (at least $316.6 million cash)

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Karyopharm Therapeutics Inc. (KPTI) Form 8-K — Nov 2, 2026: AI Analysis | Signal8